...ion=MSK treats 400+ mesothelioma cases annually with pioneering CAR T-cell therapy and clinical trials. Learn about treatment options and legal compensation.
...words=Memorial Sloan Kettering mesothelioma, MSK cancer center, CAR T-cell therapy mesothelioma, New York mesothelioma treatment, Prasad Adusumilli, Valerie R
...
29 KB (3,638 words) - 23:25, 14 May 2026
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Radiation Therapy
| style="padding:10px; border-bottom:1px solid #dee2e6;" | CAR-T Cell Therapy
...
14 KB (1,832 words) - 05:05, 25 May 2026
...67 discovery through 2020 immunotherapy approval to current CAR-T and gene therapy research.
* '''Survival Progress:''' From ~9 months untreated to 18+ months with modern therapy
...
20 KB (2,497 words) - 23:25, 14 May 2026
|title=Mesothelin CAR-T Therapy for Mesothelioma: Penn huCART-meso Phase 1 and the Clinical-Trial Landscape
...on Phase 1 (NCT03054298; PMID 41566776) of fully human anti-mesothelin CAR-T (huCART-meso); MSKCC intrapleural and NCI gavo-cel comparators.
...
51 KB (6,519 words) - 17:46, 24 May 2026
|title=CAR-T Cell Therapy for Mesothelioma: Clinical Trials, Targets & Outcomes
...trial results including 23.9-month median OS (MSK Phase I), 63.6% ORR (NAC-T cells), intrapleural delivery, engineering innovations, and 7 active trials
...
71 KB (9,331 words) - 05:04, 25 May 2026
...le:italic; border-bottom:1px solid #dee2e6;" | Immune Checkpoint Inhibitor Therapy
...t-line treatment for adults with unresectable MPM — the first new systemic therapy approved for mesothelioma in approximately 16 years, since pemetrexed plus
...
61 KB (7,899 words) - 23:55, 29 May 2026
|title=Mesothelioma Types: Pleural, Peritoneal, Pericardial & Cell Types Explained
...pes by location (pleural 75%, peritoneal 20%, pericardial, testicular) and cell type (epithelioid, sarcomatoid, biphasic). Symptoms, prognosis, treatment o
...
28 KB (3,459 words) - 13:51, 23 May 2026
| style="padding:10px;" | CAR-T, Gene Therapy
...fda-nivo-ipi" /> Today, researchers are exploring CAR-T cell therapy, gene therapy, and targeted treatments that offer hope for even greater survival improvem
...
38 KB (4,762 words) - 23:25, 14 May 2026
* '''Special Expertise:''' Sarcomatoid mesothelioma, cryoablation therapy
* '''Research Focus:''' CAR T-cell therapy, immunotherapy combinations, biomarker development
...
26 KB (3,165 words) - 23:26, 14 May 2026
...on approved CAR-T pricing for other cancers, though mesothelioma-specific therapy remains in clinical trials only
...is the most universally applied mesothelioma treatment, used as standalone therapy or combined with surgery and radiation as part of a [[Treatment Options|mul
...
39 KB (4,960 words) - 05:05, 25 May 2026
...olumab-ipilimumab, pembrolizumab), radiation therapy, TTFields, CAR-T cell therapy, multimodal approaches, and palliative care.
...pneumonectomy, radiation therapy mesothelioma, TTFields mesothelioma, CAR-T mesothelioma, palliative care mesothelioma, mesothelioma clinical trials, A
...
55 KB (6,941 words) - 05:05, 25 May 2026
...ypomethylated) subtype is enriched for ICI responders with a T cell– and B cell–rich tumor microenvironment, while the CIMP (hypermethylated) subtype is en
...or selecting pleural mesothelioma patients for immune checkpoint inhibitor therapy — and the American Society of Clinical Oncology (ASCO) 2025 mesothelioma gu
...
36 KB (4,576 words) - 21:55, 25 May 2026
...s''' for patients receiving advanced surgical approaches, while CAR-T cell therapy trials at Memorial Sloan Kettering achieve '''23.9 months median overall su
...'70+ clinical trials''' — actively recruiting studies including CAR-T cell therapy, bispecific antibodies, and TEAD inhibitors
...
38 KB (4,517 words) - 23:25, 14 May 2026
...sed on the CheckMate 743 Phase III trial; the first FDA-approved frontline therapy for unresectable MPM in 16 years.<ref name="fda-nivo-ipi" /><ref name="baas
...inhibitors (atezolizumab, durvalumab) block this binding so that activated T cells can recognize and attack tumor cells.
...
24 KB (2,899 words) - 23:07, 14 May 2026
...2026, mesothelioma clinical trials, pleurectomy decortication surgeon, CAR T mesothelioma, mesothelioma immunotherapy
...="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Gene Therapy Research
...
61 KB (8,018 words) - 23:25, 14 May 2026
|title=Gene Therapy for Mesothelioma: Clinical Trials, Vectors & Outcomes
...for mesothelioma including suicide gene therapy (HSV-tk), interferon gene therapy (TR002 Phase 3), oncolytic virotherapy (ONCOS-102), tumor suppressor replac
...
67 KB (8,772 words) - 23:06, 14 May 2026
...hemotherapy, immunotherapy combinations, surgical resection, and radiation therapy, with multimodal approaches combining these modalities offering the best ou
...g-term survival exceeding 5 years, particularly with aggressive multimodal therapy at high-volume centers, but these outcomes remain the exception rather than
...
38 KB (4,508 words) - 14:24, 21 May 2026
...ith dramatic variations based on disease location, stage at diagnosis, and cell type.<ref>[https://mesothelioma.net/mesothelioma-prognosis/ Mesothelioma Pr
| style="padding:10px; border:1px solid #dee2e6;" | '''Epithelioid cell type median survival'''
...
37 KB (4,496 words) - 23:26, 14 May 2026
...ssification by location (pleural, peritoneal, pericardial, testicular) and cell type
...hift 2020-2026: CheckMate 743, pembrolizumab approval, MARS 2 trial, CAR-T therapy
...
25 KB (2,946 words) - 12:40, 21 May 2026
...nical trials in 2026. Stage-specific eligibility, peritoneal trials, CAR-T therapy, VT3989 TEAD inhibitor Phase III, step-by-step enrollment, 93+ active trial
...2026, mesothelioma trial eligibility, peritoneal mesothelioma trials, CAR-T mesothelioma, VT3989 TEAD inhibitor, mesothelioma clinical trial enrollment
...
111 KB (14,507 words) - 23:25, 14 May 2026
